# Advances in the Diagnosis of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Integrating Conventional Tools and Emerging Biomarkers

## TL;DR

This paper reviews recent advances in diagnosing lung disease linked to rheumatoid arthritis, focusing on imaging, AI, and biomarkers.

## Contribution

The paper provides an updated review of diagnostic strategies for RA-ILD, emphasizing 2025 guidelines and emerging technologies.

## Key findings

- High-resolution computed tomography (HRCT) remains central to diagnosing RA-ILD.
- Artificial intelligence shows promise in improving HRCT-based diagnosis of RA-ILD.
- New biomarkers are being validated to enhance early detection of RA-ILD.

## Abstract

Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is one of the most common extra-articular manifestations of rheumatoid arthritis (RA) and a leading cause of mortality in RA patients. The diverse and nonspecific clinical presentations of RA-ILD make early diagnosis particularly challenging. In recent years, with a deeper understanding of the pathogenesis of RA-ILD and rapid advancements in medical imaging, artificial intelligence (AI) technologies, and biomarker research, notable progress has been achieved in the diagnostic approaches for RA-ILD. This review summarizes the latest research developments in the diagnosis of RA-ILD, with a focus on the clinical practice guidelines released in 2025. It discusses the application of high-resolution computed tomography (HRCT), the potential of AI in assisting HRCT-based diagnosis, and the discovery and validation of biomarkers. Furthermore, the review addresses current diagnostic challenges and explores future directions, providing clinicians and researchers with a cutting-edge perspective on RA-ILD diagnosis.